Chiusura precedente | 31,08 |
Aperto | 30,27 |
Denaro | 0,00 x 0 |
Lettera | 0,00 x 0 |
Min-Max giorno | 30,16 - 30,27 |
Intervallo di 52 settimane | 30,16 - 30,27 |
Volume | |
Media Volume | N/D |
Capitalizzazione | 1,957B |
Beta (5 anni mensile) | 1,11 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -4,86 |
Prossima data utili | 01 ago 2022 - 05 ago 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Parents of 4-year-old daughter with sickle cell disease kick off education campaign around World Sickle Cell Day and Father’s DaySOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced a new partnership with New York Jets running back Tevin Coleman and his wife, Akilah, whose 4-year-old daughter lives with sickle cell disease (SCD), with the goal of educating, inspiring, and raising awareness about SCD – especially among
Sickle Cell Health Awareness, Perspectives and Experiences (SHAPE) survey developed with international steering committee of medical experts and patient advocatesSOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced results from the Sickle Cell Health Awareness, Perspectives and Experiences (SHAPE) survey, a multinational survey on the burden of sickle cell disease (SCD) and unmet needs as reported by more than 1,300 pa
Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at 3:00 p.m. CEST (9:00 a.m. EDT) to highlight EHA data and provide business updates SOUTH SAN FRANCISCO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced new data from a large multicenter real-world evidence study supporting the clinical use of